A Helander1,2, M Bradley3,4, A Hasselblad3,4, L Norlén3,4, I Vassilaki5, M Bäckberg6, J Lapins3,4. 1. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Departments of Clinical Chemistry and Clinical Pharmacology, Karolinska University Laboratory, Stockholm, Sweden. 3. Dermatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 4. Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden. 5. Dermatopathology Service, Dermipath AB, Stockholm, Sweden. 6. Swedish Poisons Information Centre, Stockholm, Sweden.
Abstract
BACKGROUND: The introduction of unclassified new psychoactive substances (NPS) on the recreational drugs market through open online sale ('legal highs' or 'Internet drugs') continues unabated and represents a growing health hazard. The use of NPS has resulted in numerous, severe, adverse events and fatalities, due to unintended overdose or unknown toxic side-effects. OBJECTIVES: To try to find a possible common underlying cause for the skin-hair-eye symptoms complex observed in three men. METHODS: From late 2013 to mid-2014, three Swedish men aged 23-34 years with a history of recreational drug use independently presented with similar and very remarkable clinical signs, requiring extensive examination and prolonged treatment. RESULTS: Common clinical signs included hair depigmentation, hair loss, widespread folliculitis and dermatitis, painful intertriginous dermatitis, dry eyes, and elevated liver enzymes. Two of them also showed transverse white Mees' lines (leukonychia striata) on the fingernails and toenails, suggesting a temporary, drug-induced, disorganized keratinization. The clinical signs gradually disappeared over time. However, later on, two developed severe bilateral secondary cataracts requiring surgery. Because drug tests within the Swedish STRIDA project had demonstrated intake of the NPS opioid MT-45 in all patients, this was suspected to be the common causative agent. CONCLUSIONS: These cases highlight the importance for physicians and health professionals to consider the increasing number of novel, untested recreational drugs, as a potential cause of unusual and otherwise unrecognized clinical signs and symptoms.
BACKGROUND: The introduction of unclassified new psychoactive substances (NPS) on the recreational drugs market through open online sale ('legal highs' or 'Internet drugs') continues unabated and represents a growing health hazard. The use of NPS has resulted in numerous, severe, adverse events and fatalities, due to unintended overdose or unknown toxic side-effects. OBJECTIVES: To try to find a possible common underlying cause for the skin-hair-eye symptoms complex observed in three men. METHODS: From late 2013 to mid-2014, three Swedish men aged 23-34 years with a history of recreational drug use independently presented with similar and very remarkable clinical signs, requiring extensive examination and prolonged treatment. RESULTS: Common clinical signs included hair depigmentation, hair loss, widespread folliculitis and dermatitis, painful intertriginous dermatitis, dry eyes, and elevated liver enzymes. Two of them also showed transverse white Mees' lines (leukonychia striata) on the fingernails and toenails, suggesting a temporary, drug-induced, disorganized keratinization. The clinical signs gradually disappeared over time. However, later on, two developed severe bilateral secondary cataracts requiring surgery. Because drug tests within the Swedish STRIDA project had demonstrated intake of the NPS opioid MT-45 in all patients, this was suspected to be the common causative agent. CONCLUSIONS: These cases highlight the importance for physicians and health professionals to consider the increasing number of novel, untested recreational drugs, as a potential cause of unusual and otherwise unrecognized clinical signs and symptoms.
Authors: Michael H Baumann; Susruta Majumdar; Valerie Le Rouzic; Amanda Hunkele; Rajendra Uprety; Xi Ping Huang; Jin Xu; Bryan L Roth; Ying-Xian Pan; Gavril W Pasternak Journal: Neuropharmacology Date: 2017-08-12 Impact factor: 5.250
Authors: Renata Solimini; Simona Pichini; Roberta Pacifici; Francesco P Busardò; Raffaele Giorgetti Journal: Front Pharmacol Date: 2018-06-20 Impact factor: 5.810
Authors: Barbara Lovrecic; Mercedes Lovrecic; Branko Gabrovec; Marco Carli; Matteo Pacini; Angelo G I Maremmani; Icro Maremmani Journal: Int J Environ Res Public Health Date: 2019-01-09 Impact factor: 3.390
Authors: Craig McKenzie; Oliver B Sutcliffe; Kevin D Read; Paul Scullion; Ola Epemolu; Daniel Fletcher; Anders Helander; Olof Beck; Alexia Rylski; Lysbeth H Antonides; Jennifer Riley; Shannah A Smith; Niamh Nic Daeid Journal: Forensic Toxicol Date: 2018-04-05 Impact factor: 4.096
Authors: Daniel T Baptista-Hon; Mark Smith; Samuel Singleton; Lysbeth H Antonides; Niamh Nic Daeid; Craig McKenzie; Tim G Hales Journal: Br J Pharmacol Date: 2020-05-13 Impact factor: 8.739
Authors: Paolo Frisoni; Erica Bacchio; Sabrine Bilel; Anna Talarico; Rosa Maria Gaudio; Mario Barbieri; Margherita Neri; Matteo Marti Journal: Brain Sci Date: 2018-09-02